Adcetris Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Low Dose Tailored-Field Radiation Therapy for Unfavorable Risk Pediatric Hodgkin Lymphoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2019
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Filgrastim; Prednisolone
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 31 Jul 2019 Planned End Date changed from 30 Apr 2025 to 1 Jul 2024.
- 31 Jul 2019 Planned primary completion date changed from 31 Aug 2021 to 16 Nov 2020.
- 31 Aug 2018 Biomarkers information updated